Wyost and Jubbonti are interchangeable with Xgeva/Prolia and are approved for all of the same indications in bone cancer and ...

The study evaluated the efficacy and safety of Prolia 60 mg administered subcutaneously every six months, compared with Actonel 5 mg daily in patients receiving glucocorticoid treatment.

--Amgen today announced results from a seven-year, single-arm, open-label extension of the three-year randomized, double-blind, placebo-controlled, multicenter, international Phase 3 F racture R ...

During months 3 to 15, the women also received denosumab (60 mg subcutaneously, every 6 months). At month 15, patients who had received the high dose of teriparatide had an increase of 17.5% in ...

followed by a 1-year extension phase in which patients were randomized to either subcutaneous denosumab 60 mg every 6 months or placebo. A total of 419 postmenopausal women with low BMD enrolled ...

In the comparison of 1523 women on dialysis initiating denosumab (60 mg injection) and 1281 initiating oral bisphosphonates, severe hypocalcemia within 12 weeks occurred at a much higher rate in ...